Real-Life Use of Adjuvant Trastuzumab in Early Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

Effectiveness of adjuvant trastuzumab in patients with early-stage HER2-positive breast cancer in real life is comparable to randomized clinical trials, according to an article published online in the journal The Oncologist.

Participants of this study included patients with stage I through III invasive breast cancer (diagnosed between 2005 and 2007) from five hospitals in the southeast of The Netherlands.

Results showed that 476 patients out of 2,684 (17.7%) had a HER2-positive malignant tumor.  Although 251 (52.7%) of these patients had an indication for treatment with trastuzumab, only 196 (78.1%) actually received the treatment.

Patients treated with trastuzumab had a 5-year disease-free survival of 80.7% (n = 230) compared with a five-year disease-free survival of 68.2% (n = 246) for patients not treated with trastuzumab (P = 0.0023).

The five-year overall survival rate for the trastuzumab cohort was 90.7% versus 77.4% for the patients not treated with trastuzumab.

After adjusting for confounders, the hazard ratio for recurrence was 0.63 (95% CI: 0.37, 1.06) for trastuzumab.

The study suggests that real-life studies be considered when introducing new drugs because they can provide further insight into specific patient groups that may not be found in randomized trials.   

Patients with HER2-positive early-stage breast cancer who received neratinib had improved invasive a
Effectiveness of adjuvant trastuzumab in early-stage HER2-positive breast cancer in real life comparable to randomized clinical trials.
We investigated the use and effectiveness of adjuvant trastuzumab in daily practice compared with the effectiveness in clinical trials.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs